Invasive mould infections in the setting of hematopoietic cell transplantation: Current trends and new challenges

Current Opinion in Infectious Diseases

Volumn 22, Issue 4, 2009, Pages 376-384

  Ben Ami, Ronen ^a   Lewis, Russell E ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Galactomannan; Mould; Prophylaxis; Stem cell transplantation

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BIOLOGICAL MARKER; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; MICAFUNGIN; POLYENE; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIGEN DETECTION; ASPERGILLOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG COST; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MOULD; MYCOSIS; NEPHROTOXICITY; NUCLEIC ACID ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT RESPONSE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION CONTROL; MYCOSES;

EID: 67651114113     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32832db9f3     Document Type: Review

References (71)

1. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917.
2. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study: Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45:1161-1170.
3. Upton A, Kirby KA, Carpenter P, et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44:531-540.
4. Garcia-Vidal C, Upton A, Kirby KA, et al. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47:1041-1050. This is a detailed analysis of risk factors for IMIs in 1248 HSCT recipients. Risk factors were analyzed separately for each risk period (early and late posttransplant). The authors note that whereas host factors predominate in the early period, clinical complications of HSCT such as CMV infection and GVHD are the predominant risk factors in the late period.
5. Kontoyiannis DP, Chamilos G, Lewis RE, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 2007; 110:1303-1306.
6. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-4366.
7. Safdar A, Rodriguez GH, De Lima MJ, et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore) 2007; 86:324-333.
8. Mihu CN, King E, Yossepovitch O, et al. Risk factors and attributable mortality of late aspergillosis after T-cell depleted hematopoietic stem cell transplantation. Transpl Infect Dis 2008; 10:162-167.
9. van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalovirus and Aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13:1487-1498.
10. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102:2768-2776.
11. Labbe AC, Su SH, Laverdiere M, et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant 2007; 13:1192-1200.
12. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40:451-456.
13. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39:425-429.
14. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265-273. The PATH registry is an extensive, prospectively collected multicenter database of invasive fungal infections in HSCT recipients. A key observation in this study is that whereas the survival of patients with invasive aspergillosis is improving, that of patients with non-Aspergillus moulds remains poor. These diverging trends suggest that more attention should be directed towards the treatment of emerging mould infections such as mucormycosis.
15. Kojima R, Tateishi U, Kami M, et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:506-511.
16. Cordonnier C, Botterel F, Ben AR, et al. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 2009; 15:81-86. Data about the galactomannan immunoassay is mostly derived from neutropenic patients, and its performance in nonneutropenic patients is unknown. This study compared the galactomannan index in neutropenic and nonneutropenic patients, and found significantly higher values in severely neutropenic patients.
17. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis instem-celltransplantation. N EnglJ Med 2008;359:1766-1777. This study examined the role of TLR polymorphisms in post-HSCT invasive aspergillosis. A SNP in the donor TLR4 gene was associated with a significant independent risk of invasive aspergillosis. By examining two separate (discovery and validation) cohorts, the authors were able to reduce the likelihood that these observations were population-specific.
18. Kesh S, Mensah NY, Peterlongo P, et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005; 1062:95-103.
19. Mezger M, Steffens M, Beyer M, et al. Polymorphisms in the chemokine (C-X-C motif) ligand 10 are associated with invasive aspergillosis after allogeneic stem-cell transplantation and influence CXCL10 expression in monocyte-derived dendritic cells. Blood 2008; 111:534-536. This study identified an association between SNPs in the CXCL-10 gene and invasive aspergillosis in HSCT recipients. Furthermore, there was reduced expression of CXCL-10 following stimulation with Aspergillus fumigatus germlings in immature dendritic cells carrying these SNPs.
20. Sainz J, Perez E, Hassan L, et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007; 68:41-50.
21. Sainz J, Hassan L, Perez E, et al. Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis. Immunol Lett 2007; 109:76-82.
22. Sainz J, Perez E, Gomez-Lopera S, et al. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol 2008; 28:473-485.
23. Zaas AK, Liao G, Chien JW, et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 2008; 4:e1000101. The authors used an animal model to identify polymorphisms in the plasminogen gene that influence host susceptibility to invasive aspergillosis. They then validated these findings in human HSCT patients. The design of this study might serve as a blueprint for future discovery of clinically important SNPs.
24. Seo KW, Kim DH, Sohn SK, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36:1089-1095.
25. Ferwerda B, McCall MB, Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 2007; 104:16645-16650.
26. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-1552.
27. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360. Extensively updated guidelines for the management of different forms of aspergillosis.
28. Maertens J, Frere P, Lass-Florl C, et al. 2007 update of the ECIL-1 guidelines for antifungal prophylaxis in leukemia patients, including allogeneic HSCT recipients. Proceedings of the 2nd European Conference on Infections in Leukemia (ECIL-2). Juan-les-Pins, France.
29. National Comprehensive Cancer Network. Prevention and treatment of cancer related infections. http://www.nccn.org/professionals/physician-gls/PDF/ infections.pdf (Accessed on 13 January 2009).
30. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347.
31. Wingard JR, Carter SL, Walsh TJ, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 2007; 110 (American Society for Hematology Annual Meeting, Abstract 163).
32. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532-1535.
33. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27:1627-1636.
34. Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46:828-833.
35. Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31:135-141.
36. El-Cheikh J, Faucher C, Furst S, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:301-306.
37. Maertens J, Buve K, Anaissie E. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. J Natl Compr Canc Netw 2008; 6:183-189.
38. Gonzalez AV, Ullmann AJ, Almyroudis NG, et al. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. J Natl Compr Canc Netw 2008; 6:175-182.
39. Nivoix Y, Velten M, Letscher-Bru V, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47:1176-1184. This is a detailed analysis of risk factors for death in patients with invasive aspergillosis. Importantly, patients with proven or probable invasive aspergillosis had higher mortality than patients with possible invasive aspergillosis, suggesting that earlier diagnosis and treatment of this condition could improve survival.
40. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41:1242-1250.
41. Barnes RA, White PL, Bygrave C, et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 2009; 62:64-69.
42. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive anti-fungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48:1042-1051.
43. Chou LS, Lewis RE, Ippoliti C, et al. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 2007; 27:1644-1650.
44. Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007; 30:551-554.
45. Goldberg E, Gafter-Gvili A, Robenshtok E, et al. Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer 2008; 44:2192-2203.
46. Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009; 11:89-93.
47. Maertens J, Bryan J. Recent progress in the management of invasive fungal infections in hematopoietic stem cell transplant recipients. 34th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), March 30-April 2, 2008, Florence, Italy. Future Microbiol 2008; 3:493-496.
48. Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20:1898-1906.
49. Foy PC, van Burik JA, Weisdorf DJ. Galactomannan antigen enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:440-443.
50. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821. The recently revised definitions of invasive fungal disease have addressed some of the problems in previous definitions, especially with regards to the 'probable' category. The (1→3) beta-D glucan assay has been added as a microbiologic criterion. However, lack of standardization has prevented Aspergillus PCR from being incorporated into these guidelines.
51. Obayashi T, Negishi K, Suzuki T, et al. Reappraisal of the serum (1->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections-a study based on autopsy cases from 6 years. Clin Infect Dis 2008; 46:1864-1870. An autopsy-based analysis of the performance of the (1→3)-beta-D-glucan assay for the diagnosis of invasive fungal infections. High sensitivity of this assay could complement the variable sensitivity of the galactomannan assay.
52. Klingspor L. Aspergillus PCR: formidable challenges and progress. Proceedings of the 3rd Advances Against Aspergillosis, 16 January 2007; Miami, FL.
53. Suarez F, Lortholary O, Buland S, et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol 2008; 46:3772-3777.
54. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45:e101-e104.
55. Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10:494-503.
56. Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998; 26:1098-1103.
57. Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108:2928-2936.
58. Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33:943-948.
59. Allinson K, Kolve H, Gumbinger HG, et al. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008; 61:734-742.
60. Hill BT, Kondapalli L, Artz A, et al. Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leuk Lymphoma 2007; 48:1799-1805.
61. Mullane K, Toor AA, Kalnicky C, et al. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis 2007; 9:89-96.
62. Kruger WH, Russmann B, de WM, et al. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005; 113:104-108.
63. Cornely O, Martino R, Maschmeyer G. Efficacy of caspofungin as secondary antifungal prophylaxis for prevention of breakthrough fungal infection: data from a multinational case registry. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC: American Society for Microbiology; 2005.
64. Stute N, Kratochwille A, Zabelina T, et al. Caspofungin is highly effective as secondary prophylaxis in allogeneic stem cell transplantation in patients with prior systemic or invasive fungal infections. Bone Marrow Transplant 2004; 33 (Suppl 1):S191.
65. Grigg A, Slavin M. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy. Transpl Infect Dis 2008; 10:3-12. This extensive review summarizes the evidence about strategies to prevent recurrence during HSCT in patients who have a history of IFI. The authors provide a framework for decision making in these challenging cases.
66. Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006; 42:1584-1591.
67. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253-259.
68. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007; 110:112-120.
69. Maertens J, Buve K, Theunissen K, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 2008; 115:355-362. This study found good correlation between the Aspergillus galactomannan index and clinical patient outcomes, suggesting that the galactomannan index could serve as a surrogate endpoint in clinical practice and in studies of invasive aspergillosis.
70. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412-1422. This review of published data explored the correlation between the galactomannan index and clinical patient outcomes. A strong correlation was found, lending support to the notion that the galactomannan index could serve as a surrogate endpoint to assess response in invasive aspergillosis.
71. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47:674-683. These recently published guidelines address, for the first time, criteria for defining response, partial response, and therapeutic failure in a range of invasive mycoses.